

# Munther A Khamashta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10731361/publications.pdf>

Version: 2024-02-01

152  
papers

27,944  
citations

15466

65  
h-index

10708

138  
g-index

164  
all docs

164  
docs citations

164  
times ranked

16159  
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop. <i>Arthritis and Rheumatism</i> , 1999, 42, 1309-1311.	6.7	2,512
3	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , 2002, 46, 1019-1027.	6.7	1,736
4	The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome. <i>New England Journal of Medicine</i> , 1995, 332, 993-997.	13.9	1,407
5	Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period. <i>Medicine (United States)</i> , 1994, 73, 107-114.	0.4	1,107
6	Adult haemophagocytic syndrome. <i>Lancet</i> , The, 2014, 383, 1503-1516.	6.3	1,013
7	Antiphospholipid syndrome. <i>Lancet</i> , The, 2010, 376, 1498-1509.	6.3	916
8	The "Primary" Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 1989, 68, 366-374.	0.4	838
9	Systemic lupus erythematosus. <i>Lancet</i> , The, 2007, 369, 587-596.	6.3	783
10	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
11	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.5	664
12	Autoimmune Diseases Induced by TNF-Targeted Therapies. <i>Medicine (United States)</i> , 2007, 86, 242-251.	0.4	624
13	Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. <i>American Journal of Medicine</i> , 1994, 96, 3-9.	0.6	484
14	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
15	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	0.9	370
16	Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients. <i>Medicine (United States)</i> , 1999, 78, 167-175.	0.4	367
17	Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. <i>American Journal of Medicine</i> , 1989, 86, 391-399.	0.6	358
18	Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. <i>Journal of Rheumatology</i> , 2003, 30, 985-92.	1.0	317

#	ARTICLE	IF	CITATIONS
19	A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2007, 57, 1487-1495.	6.7	294
20	Autoimmune diseases induced by biological agents. <i>Autoimmunity Reviews</i> , 2010, 9, 188-193.	2.5	282
21	Systemic lupus erythematosus. <i>Lancet, The</i> , 2001, 357, 1027-1032.	6.3	271
22	Autoimmune diseases induced by TNF-targeted therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 847-861.	1.4	260
23	Statins prevent endothelial cell activation induced by antiphospholipid (anti- $\beta$ 2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. <i>Arthritis and Rheumatism</i> , 2001, 44, 2870-2878.	6.7	250
24	GAPSS: the Global Anti-Phospholipid Syndrome Score. <i>Rheumatology</i> , 2013, 52, 1397-1403.	0.9	248
25	Systemic lupus erythematosus and pregnancy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 685-694.	1.4	236
26	The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2009, 119, 1066-1073.	3.9	229
27	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012, 11, 357-364.	2.5	209
28	The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , 2015, 11, 301-312.	3.5	209
29	Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. <i>Arthritis and Rheumatism</i> , 1997, 40, 834-841.	6.7	204
30	Oxidation of LDL and its clinical implication. <i>Autoimmunity Reviews</i> , 2008, 7, 558-566.	2.5	195
31	Management of the obstetric antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2004, 50, 1028-1039.	6.7	194
32	Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1995, 99, 397-401.	0.6	186
33	Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1994, 37, 568-571.	6.7	172
34	Circulating oxidized LDL forms complexes with $\beta$ 2-glycoprotein I: implication as an atherogenic autoantigen. <i>Journal of Lipid Research</i> , 2003, 44, 716-726.	2.0	165
35	Bleeding and Recurrent Thrombosis in Definite Antiphospholipid Syndrome. <i>Archives of Internal Medicine</i> , 2002, 162, 1164.	4.3	163
36	Can Neurologic Manifestations of Hughes (Antiphospholipid) Syndrome Be Distinguished from Multiple Sclerosis?: Analysis of 27 Patients and Review of the Literature. <i>Medicine (United States)</i> , 2000, 79, 57-68.	0.4	152

#	ARTICLE	IF	CITATIONS
37	Î2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 1994, 37, 1453-1461.	6.7	150
38	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.5	143
39	Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. <i>Obstetrics and Gynecology</i> , 2003, 101, 1333-1344.	1.2	136
40	Google-driven search for big data in autoimmune geoeidemiology: Analysis of 394,827 patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2015, 14, 670-679.	2.5	135
41	High Prevalence of Significant Heart Valve Lesions in Patients with the 'Primary' Antiphospholipid Syndrome. <i>Lupus</i> , 1991, 1, 43-47.	0.8	132
42	Long-Term Follow-Up in 128 Patients With Primary Antiphospholipid Syndrome. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50)</i> , 2015, 94, 125.	0.4	125
43	Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. <i>Arthritis and Rheumatism</i> , 1998, 41, 800-807.	6.7	124
44	The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2028-2033.	0.5	124
45	Thrombocytopenia in the antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 194-196.	0.5	113
46	Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. <i>Journal of Rheumatology</i> , 2004, 31, 280-5.	1.0	113
47	Obstetric outcome in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1995, 25, 184-192.	1.6	111
48	SYSTEMIC LUPUS ERYTHEMATOSUS FLARES DURING PREGNANCY. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 15-30.	0.8	107
49	Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. <i>Arthritis and Rheumatism</i> , 1998, 41, 1420-1427.	6.7	106
50	Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called "seronegative APS"™). <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 242-244.	0.5	105
51	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	2.9	98
52	A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies. <i>Arthritis and Rheumatism</i> , 1999, 42, 2461-2470.	6.7	91
53	Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. <i>Journal of Rheumatology</i> , 2004, 31, 2480-7.	1.0	90
54	The global anti-phospholipid syndrome score in primary APS. <i>Rheumatology</i> , 2015, 54, 134-138.	0.9	87

#	ARTICLE	IF	CITATIONS
55	Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. <i>Journal of Neurology</i> , 2014, 261, 1706-1714.	1.8	86
56	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
57	Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1441-1449.	0.5	76
58	Release of calreticulin from neutrophils may alter C1q-mediated immune functions. <i>Biochemical Journal</i> , 1997, 322, 543-550.	1.7	74
59	Neuropsychiatric Involvement in Systemic Lupus Erythematosus: Current Therapeutic Approach. <i>Current Pharmaceutical Design</i> , 2008, 14, 1261-1269.	0.9	74
60	Management of antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2009, 33, 92-98.	3.0	70
61	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.5	70
62	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	1.5	70
63	Antiendothelial Cell Antibodies in Patients with the Antiphospholipid Syndrome. <i>Autoimmunity</i> , 1991, 11, 1-6.	1.2	66
64	B-cell-depleting Therapy in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2012, 125, 327-336.	0.6	66
65	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018, 47, 639-646.	1.8	62
66	Vasculitis induced by tumor necrosis factor-targeted therapies. <i>Current Rheumatology Reports</i> , 2008, 10, 442-448.	2.1	61
67	Lupus and pregnancy: integrating clues from the bench and bedside. <i>European Journal of Clinical Investigation</i> , 2011, 41, 672-678.	1.7	60
68	Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. <i>Autoimmunity Reviews</i> , 2013, 12, 426-429.	2.5	58
69	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
70	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	2.9	55
71	Management of refractory anti-phospholipid syndrome. <i>Autoimmunity Reviews</i> , 2011, 10, 669-673.	2.5	52
72	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 391-399.	1.6	52

#	ARTICLE	IF	CITATIONS
73	Systemic Lupus Erythematosus: Sex Hormones in Male Patients. <i>Lupus</i> , 1993, 2, 315-317.	0.8	49
74	Role of the Fc $\gamma$ receptor IIA polymorphism in the antiphospholipid syndrome: An international meta-analysis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1930-1938.	6.7	49
75	Management of Thrombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Pregnancy. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 606-612.	1.8	46
76	Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al. <i>Arthritis and Rheumatism</i> , 2009, 61, 1281-1282.	6.7	46
77	B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. <i>Journal of Autoimmunity</i> , 2013, 43, 55-59.	3.0	46
78	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42
79	Thrombosis and Antiphospholipid Syndrome: a Preliminary Assessment of Three Antithrombotic Treatments. <i>Lupus</i> , 1994, 3, 85-90.	0.8	41
80	Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 181, 180-189.	0.7	41
81	MANAGEMENT OF PREGNANCY IN ANTIPHOSPHOLIPID SYNDROME. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 643-659.	0.8	40
82	Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2012, 12, 230-234.	2.5	40
83	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	2.9	40
84	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
85	Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 159-169.	2.9	37
86	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	0.9	37
87	Managing lupus patients during pregnancy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 575-582.	1.4	36
88	Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 1999, 42, 2606-2611.	6.7	35
89	Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 339-347.	1.5	35
90	How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. <i>Blood</i> , 2007, 110, 3122-3127.	0.6	33

#	ARTICLE	IF	CITATIONS
91	Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. <i>Rheumatology</i> , 2015, 54, 1582-1586.	0.9	33
92	ANTIPHOSPHOLIPID (HUGHES) SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 331-348.	0.8	32
93	Cardiac valve replacement in patients with antiphospholipid syndrome. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	1.5	32
94	Up-Regulated Tissue Factor Expression in Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 1997, 77, 222-223.	1.8	32
95	New Tests to Detect Antiphospholipid Antibodies: Antiprothrombin (aPT) and Anti-Phosphatidylserine/Prothrombin (aPS/PT) Antibodies. <i>Current Rheumatology Reports</i> , 2014, 16, 415.	2.1	30
96	Antiphospholipid (Hughes) Syndrome. <i>Autoimmunity</i> , 2004, 37, 309-312.	1.2	29
97	Diagnosis of antiphospholipid syndrome. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 40-46.	3.2	29
98	Hughes syndrome crosses boundaries. <i>Autoimmunity Reviews</i> , 2002, 1, 43-48.	2.5	26
99	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	2.9	26
100	Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. <i>Thrombosis Research</i> , 2014, 133, 451-454.	0.8	25
101	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	2.9	25
102	The anti-phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000, 14, 151-163.	1.4	23
103	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	1.5	23
104	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	1.5	21
105	Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 860-866.	1.6	20
106	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.4	19
107	Therapy of systemic lupus erythematosus: new agents and new evidence. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1581-1593.	1.9	18
108	Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus. <i>Lupus</i> , 2003, 12, 1-2.	0.8	18

#	ARTICLE	IF	CITATIONS
109	The treatment of antiphospholipid syndrome: A harmonic contrast. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 1079-1092.	1.4	18
110	Targeted therapy in antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2014, 26, 269-275.	2.0	17
111	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	2.9	17
112	IgG2 restriction of anti- $\beta_2$ -glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: Comment on the article by Sammaritano et al. <i>Arthritis and Rheumatism</i> , 1998, 41, 1513-1514.	6.7	16
113	Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?. <i>Immunologic Research</i> , 2017, 65, 230-241.	1.3	15
114	6 Antiphospholipid syndrome in SLE. <i>Bailliere's Clinical Rheumatology</i> , 1998, 12, 477-493.	1.0	14
115	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	1.5	13
116	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
117	Antiphospholipid antibodies. <i>Clinical Reviews in Allergy</i> , 1994, 12, 287-296.	1.0	12
118	An evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of arterial thrombosis in patients with the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 1655-1656.	6.7	11
119	Natural immune response involving anti-endothelial cell antibodies in normal and lupus pregnancy. <i>Arthritis and Rheumatism</i> , 2000, 43, 1511-1515.	6.7	10
120	Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?. <i>Current Rheumatology Reports</i> , 2013, 15, 318.	2.1	9
121	Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. <i>Autoimmunity Reviews</i> , 2018, 17, 256-266.	2.5	9
122	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	1.5	9
123	Aspirin to treat obstetric manifestations of the antiphospholipid syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, 523-524.	0.7	8
124	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	0.9	8
125	Phospholipid Autoantibodies " Cardiolipin. , 1996, , 624-629.		6
126	The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 659-668.	1.3	5



#	ARTICLE	IF	CITATIONS
127	Lupus, thrombotic thrombocytopenic purpura, and antiphospholipid antibodies. <i>Annals of Neurology</i> , 1989, 25, 312-313.	2.8	4
128	Antiphospholipid antibodies and valve disease in patients with systemic lupus erythematosus. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1269.	1.2	4
129	Antiphospholipid syndrome: treatment controversies. <i>Future Rheumatology</i> , 2006, 1, 345-353.	0.2	3
130	The clinical aspects of the antiphospholipid syndrome. , 2004, , 1107-1123.		2
131	The Importance of Antiphospholipid Antibodies. <i>Ophthalmology</i> , 1990, 97, 150-151.	2.5	1
132	Antiphospholipid antibodies in sickle cell disease. <i>American Journal of Hematology</i> , 1994, 45, 193-194.	2.0	1
133	Anticardiolipin Antibodies and Cardiovascular Disease. <i>Journal of the Royal Society of Medicine</i> , 1996, 89, 119-119.	1.1	1
134	The antiphospholipid syndrome. <i>European Journal of Internal Medicine</i> , 1999, 10, 191-197.	1.0	1
135	Diagnosis of antiphospholipid syndrome. <i>Expert Review of Hematology</i> , 2008, 1, 183-188.	1.0	1
136	THE CLINICAL ASPECTS OF THE ANTIPHOSPHOLIPID SYNDROME. , 2004, , 1107-1123.		1
137	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1
138	What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 779-781.	1.3	1
139	ANTICARDIOLIPIN ANTIBODIES. , 2007, , 741-745.		0
140	Comments on the Editorial "Antiphospholipid Syndrome: New Clinical and Therapeutic Perspectives" • <i>Reumatología Clínica (English Edition)</i> , 2007, 3, 90.	0.2	0
141	Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 185-191.	0.1	0
142	Chapter 17 Treatment of Late Pregnancy Complications in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 203-214.	0.1	0
143	Clinical Presentation of Antiphospholipid Syndrome. , 2011, , 1001-1014.		0
144	CS-07...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
145	Clinical presentation of antiphospholipid syndrome. , 2021, , 561-574.		0
146	Systemic Lupus Erythematosus, Antiphospholid Syndrome, Scleroderma, and Inflammatory Myopathies. , 2001, , 69-95.		0
147	Management of APS. , 2010, , 69-77.		0
148	Differences Between Primary and Secondary APS. , 2010, , 19-20.		0
149	Targeting B Cells in Other Systemic Autoimmune Diseases. Milestones in Drug Therapy, 2014, , 247-258.	0.1	0
150	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. Milestones in Drug Therapy, 2014, , 79-95.	0.1	0
151	801â€¦Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
152	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	0.9	0